Gujarat Themis Biosyn has reported its Q2 FY27 financial performance following a board meeting on November 14, 2026. Market alerts indicate Q2 revenue of ₹47.45 crore versus ₹42.30 crore YoY (as stated in the source alert; not independently verified). The company continues to advance its active pharmaceutical ingredient and fermentation capabilities alongside strategic inorganic expansion.
Gujarat Themis Biosyn Considers And Approves Q2 FY27 Financial Results
calendar_today
November 14, 2026
domain
sahi